IL129211A - Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders - Google Patents
Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disordersInfo
- Publication number
- IL129211A IL129211A IL12921197A IL12921197A IL129211A IL 129211 A IL129211 A IL 129211A IL 12921197 A IL12921197 A IL 12921197A IL 12921197 A IL12921197 A IL 12921197A IL 129211 A IL129211 A IL 129211A
- Authority
- IL
- Israel
- Prior art keywords
- colostrinin
- pharmaceutical composition
- treatment
- medicament
- composition according
- Prior art date
Links
- 108010002212 colostrinine Proteins 0.000 title claims abstract description 117
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 208000015114 central nervous system disease Diseases 0.000 title description 3
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 14
- 208000017667 Chronic Disease Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 20
- 239000003826 tablet Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 5
- 238000011161 development Methods 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 108010020048 valyl-glutamyl-seryl-tyrosyl-valyl-prolyl-leucyl-phenylalanylproline Proteins 0.000 claims description 5
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 206010029333 Neurosis Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015238 neurotic disease Diseases 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000006186 oral dosage form Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 210000003022 colostrum Anatomy 0.000 description 25
- 235000021277 colostrum Nutrition 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- 210000004698 lymphocyte Anatomy 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 108010050904 Interferons Proteins 0.000 description 12
- 102000014150 Interferons Human genes 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 241001494479 Pecora Species 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004700 fetal blood Anatomy 0.000 description 7
- 206010003402 Arthropod sting Diseases 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000032696 parturition Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 235000002198 Annona diversifolia Nutrition 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282838 Lama Species 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004970 emotional disturbance Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000000686 immunotropic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000282832 Camelidae Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 2
- 229940005660 ethylmercurithiosalicylic acid Drugs 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- XRFXFAVKXJREHL-UHFFFAOYSA-N arsinine Chemical compound [As]1=CC=CC=C1 XRFXFAVKXJREHL-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003718 diatrizoate sodium Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL96316416A PL185442B1 (pl) | 1996-10-03 | 1996-10-03 | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
| PCT/GB1997/002721 WO1998014473A1 (en) | 1996-10-03 | 1997-10-03 | Colostrinin, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL129211A0 IL129211A0 (en) | 2000-02-17 |
| IL129211A true IL129211A (en) | 2004-08-31 |
Family
ID=20068412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12921197A IL129211A (en) | 1996-10-03 | 1997-10-03 | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6852700B1 (cs) |
| EP (1) | EP0932623A1 (cs) |
| JP (2) | JP2001501929A (cs) |
| KR (2) | KR20050046766A (cs) |
| CN (2) | CN1535722A (cs) |
| AR (1) | AR013612A1 (cs) |
| AU (1) | AU4565197A (cs) |
| BR (1) | BR9712259A (cs) |
| CA (1) | CA2266859C (cs) |
| CZ (1) | CZ298215B6 (cs) |
| GB (1) | GB2333453B (cs) |
| HU (1) | HUP9904368A3 (cs) |
| IL (1) | IL129211A (cs) |
| PL (1) | PL185442B1 (cs) |
| RU (1) | RU2217152C2 (cs) |
| TR (1) | TR199901022T2 (cs) |
| WO (1) | WO1998014473A1 (cs) |
| ZA (1) | ZA978885B (cs) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL185442B1 (pl) | 1996-10-03 | 2003-05-30 | Georgiades Biotech Ltd | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
| CZ20004256A3 (cs) | 1998-05-27 | 2001-09-12 | Gemma Biotechnology Ltd. | Indukce antibiotických proteinů a peptidů LAIT/sCD14-proteinem |
| ATE322275T1 (de) * | 1998-06-10 | 2006-04-15 | Albert B Crum | Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems |
| GB9813031D0 (en) * | 1998-06-16 | 1998-08-12 | Regen Biotech Limited | Dietary supplement |
| GB9912852D0 (en) * | 1999-06-02 | 1999-08-04 | Regen Therapeutics Plc | Peptides |
| US6903068B1 (en) * | 1999-08-17 | 2005-06-07 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
| EP1238058B1 (en) * | 1999-08-17 | 2007-10-03 | The University Of Texas System | Use of colostrinin, constituent peptides and analogs thereof to promote neural cell differentiation |
| EP1224217A4 (en) * | 1999-08-17 | 2006-05-24 | Univ Texas | USE OF COLOSTRININE, ITS CONSTITUENT PEPTIDES AND ITS ANALOGUES FOR ACTIVATING CYTOKINES |
| AU7061700A (en) | 1999-08-17 | 2001-03-13 | University Of Texas System, The | Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators |
| US7119064B2 (en) * | 1999-08-17 | 2006-10-10 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules |
| US6852685B1 (en) * | 1999-08-17 | 2005-02-08 | Board Of Regents, The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation |
| GB0001825D0 (en) * | 2000-01-26 | 2000-03-22 | Regen Therapeutics Plc | Peptides |
| WO2002013850A1 (en) * | 2000-08-17 | 2002-02-21 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators |
| AU2000267883A1 (en) * | 2000-08-17 | 2002-02-25 | Regen Therapeutics Plc | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
| WO2002013851A1 (en) * | 2000-08-17 | 2002-02-21 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neural cell differentiation |
| GB0029777D0 (en) * | 2000-12-06 | 2001-01-17 | Regen Therapeutics Plc | Peptides |
| HUP0200172A2 (hu) * | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| EP1567551A4 (en) * | 2002-10-22 | 2008-03-12 | Univ Texas | COLOSTRININE AND PEPTIDES THEREOF AS MODULATORS OF INTRACELLULAR SIGNALING MOLECULES AND INHIBITORS OF APOPTOSIS |
| DE602004010636T2 (de) * | 2003-03-11 | 2008-12-11 | Regen Therapeutics Plc | Aufreinigung von peptiden aus kolostrum |
| CN1313487C (zh) * | 2003-06-10 | 2007-05-02 | 天津商学院 | 具有抗菌作用的免疫活性肽（Trpi） |
| WO2005041680A2 (en) * | 2003-11-03 | 2005-05-12 | Advanced Protein Systems | A novel colostral fractionation process |
| EP1723951A1 (en) * | 2005-04-21 | 2006-11-22 | N.V. Nutricia | Nutritional supplement with oligosaccharides for a category of HIV patients |
| US20070212367A1 (en) * | 2006-03-13 | 2007-09-13 | Keech Andrew M | Novel immunologically active peptide fragments of a proline-rich polypeptide isolated from colostral mammalian fluids for treatment of viral and non-viral diseases or diseased conditions |
| GB2436328A (en) * | 2006-03-22 | 2007-09-26 | Regen Therapeutics Plc | Peptide derived from colostrinin |
| US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
| ITMI20111460A1 (it) * | 2011-07-29 | 2013-01-30 | Bionest Ltd | Composizioni per la terapia adiuvante dell'anoressia comprendenti anticorpi, fattori di crescita e citochine isolati dal colostro dei mammiferi |
| ES2609352T3 (es) | 2011-12-30 | 2017-04-19 | Innomed S.A. | Combinación de factores de crecimiento, citoquinas, factores antibacterianos/antivíricos, factores estimulantes de células madre, proteínas del complemento C3a/C4a, inmunoglobulinas y factores quimiotácticos |
| ITMI20112433A1 (it) * | 2011-12-30 | 2013-07-01 | Bionest Ltd | Composizioni per la terapia orale adiuvante dell'anoressia comprendenti anticorpi, antibatterici, fattori di crescita e citochine |
| WO2013098331A1 (en) | 2011-12-30 | 2013-07-04 | Bionest Ltd. | Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, and chemotactic factors |
| GB201205856D0 (en) | 2012-04-02 | 2012-05-16 | Randall Jeremy A P | Food supplement to support brain function |
| PL235821B1 (pl) * | 2014-11-04 | 2020-11-02 | Geo Poland Spolka Z Ograniczona Odpowiedzialnoscia | Wysokoprolinowy kompleks peptydowy do zastosowania w profilaktyce i wspomaganiu leczenia zaburzeń i stanów wymagających podwyższania i/lub modulacji poziomu neurotropowego czynnika pochodzenia mózgowego jako oznaczonego w osoczu krwi biomarkera i zawierający go preparat |
| DE112015005883T5 (de) | 2015-01-30 | 2017-09-28 | Hewlett-Packard Development Company, L.P. | M-äre zyklische codierung |
| US12263192B2 (en) | 2019-02-26 | 2025-04-01 | Pantheryx, Inc. | Compositions for management of disorders of the gastrointestinal tract |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE90569T1 (de) | 1988-04-19 | 1993-07-15 | Biotest Pharma Gmbh | Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen. |
| JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
| JP3174611B2 (ja) * | 1992-02-28 | 2001-06-11 | 明治乳業株式会社 | 免疫賦活組成物 |
| US5645834A (en) | 1992-08-28 | 1997-07-08 | Immuno-Dynamics, Inc. | Method and product for treating failure of passive transfer and improving milk production in bovine species |
| GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| DE4337654C2 (de) | 1993-11-04 | 1996-08-08 | Biotest Pharma Gmbh | Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat |
| JP4112021B2 (ja) * | 1994-02-16 | 2008-07-02 | 明治乳業株式会社 | 乳酸菌を用いた免疫賦活剤 |
| RU2062109C1 (ru) * | 1994-11-28 | 1996-06-20 | Товарищество с ограниченной ответственностью "Старк" | Способ получения иммунного препарата |
| WO1997005884A1 (en) | 1995-08-07 | 1997-02-20 | New England Medical Center Hospitals, Inc. | Infant formula and infant formula additives |
| DE19619990A1 (de) | 1996-05-17 | 1997-11-20 | Charlotte Adler | Verfahren zur Herstellung von Kolostralmilchprodukten sowie deren Verwendung |
| PL185442B1 (pl) | 1996-10-03 | 2003-05-30 | Georgiades Biotech Ltd | Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie |
-
1996
- 1996-10-03 PL PL96316416A patent/PL185442B1/pl not_active IP Right Cessation
-
1997
- 1997-10-03 ZA ZA9708885A patent/ZA978885B/xx unknown
- 1997-10-03 CA CA2266859A patent/CA2266859C/en not_active Expired - Fee Related
- 1997-10-03 GB GB9908331A patent/GB2333453B/en not_active Expired - Fee Related
- 1997-10-03 AR ARP970104585A patent/AR013612A1/es unknown
- 1997-10-03 CZ CZ0114999A patent/CZ298215B6/cs not_active IP Right Cessation
- 1997-10-03 TR TR1999/01022T patent/TR199901022T2/xx unknown
- 1997-10-03 IL IL12921197A patent/IL129211A/en not_active IP Right Cessation
- 1997-10-03 EP EP97944005A patent/EP0932623A1/en not_active Withdrawn
- 1997-10-03 BR BR9712259-9A patent/BR9712259A/pt not_active Application Discontinuation
- 1997-10-03 JP JP10516329A patent/JP2001501929A/ja active Pending
- 1997-10-03 WO PCT/GB1997/002721 patent/WO1998014473A1/en not_active Ceased
- 1997-10-03 RU RU99109093/15A patent/RU2217152C2/ru not_active IP Right Cessation
- 1997-10-03 KR KR1020057004215A patent/KR20050046766A/ko not_active Ceased
- 1997-10-03 US US09/269,845 patent/US6852700B1/en not_active Expired - Lifetime
- 1997-10-03 CN CNA031466095A patent/CN1535722A/zh active Pending
- 1997-10-03 AU AU45651/97A patent/AU4565197A/en not_active Abandoned
- 1997-10-03 CN CN97198535A patent/CN1131712C/zh not_active Expired - Fee Related
- 1997-10-03 KR KR10-1999-7002904A patent/KR100508764B1/ko not_active Expired - Fee Related
- 1997-10-03 HU HU9904368A patent/HUP9904368A3/hu unknown
-
2004
- 2004-12-03 US US11/003,854 patent/US20050152985A1/en not_active Abandoned
-
2008
- 2008-02-13 JP JP2008031513A patent/JP2008174561A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998014473A1 (en) | 1998-04-09 |
| PL316416A1 (en) | 1998-04-14 |
| GB2333453B (en) | 2001-05-30 |
| KR20000048886A (ko) | 2000-07-25 |
| IL129211A0 (en) | 2000-02-17 |
| CN1535722A (zh) | 2004-10-13 |
| AR013612A1 (es) | 2001-01-10 |
| JP2001501929A (ja) | 2001-02-13 |
| GB2333453A8 (en) | 2000-11-27 |
| GB2333453A (en) | 1999-07-28 |
| CN1131712C (zh) | 2003-12-24 |
| CA2266859C (en) | 2012-05-08 |
| US20050152985A1 (en) | 2005-07-14 |
| TR199901022T2 (xx) | 1999-07-21 |
| CZ114999A3 (cs) | 2000-06-14 |
| KR100508764B1 (ko) | 2005-08-17 |
| BR9712259A (pt) | 2000-01-25 |
| EP0932623A1 (en) | 1999-08-04 |
| GB9908331D0 (en) | 1999-06-09 |
| HUP9904368A3 (en) | 2000-07-28 |
| CA2266859A1 (en) | 1998-04-09 |
| PL185442B1 (pl) | 2003-05-30 |
| HUP9904368A2 (hu) | 2000-06-28 |
| KR20050046766A (ko) | 2005-05-18 |
| JP2008174561A (ja) | 2008-07-31 |
| CN1238782A (zh) | 1999-12-15 |
| AU4565197A (en) | 1998-04-24 |
| US6852700B1 (en) | 2005-02-08 |
| CZ298215B6 (cs) | 2007-07-25 |
| RU2217152C2 (ru) | 2003-11-27 |
| ZA978885B (en) | 1999-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6852700B1 (en) | Colostrinin, and uses thereof | |
| JPH10509955A (ja) | 二次性免疫不全症の治療法 | |
| US4250084A (en) | Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it | |
| JP2607751B2 (ja) | 自己免疫性ブドウ膜網膜炎の治療予防薬 | |
| JPH09502706A (ja) | 胆汁由来免疫調節組成物 | |
| JP5247429B2 (ja) | カゼイン由来ペプチドを含む医薬組成物及びその使用方法 | |
| EP0190099B1 (en) | Polypeptide factors from colostrum | |
| US20050085422A1 (en) | Peptides derived from colostrinin | |
| EP0655925B1 (en) | Anti-cancer therapeutic compositions containing whey protein concentrate | |
| AU761148B2 (en) | Colostrinin, and uses thereof | |
| US9249188B2 (en) | Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof | |
| EP1224217A2 (en) | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines | |
| Artym et al. | An overview on immunological activity of calf thymus extract (TFX®) and its therapeutic benefits | |
| GB2352176A (en) | Colostrinin and uses thereof | |
| EP1375513A1 (en) | Immunopotentiators | |
| MXPA99003108A (en) | Colostrinin, and uses thereof | |
| Seino et al. | Inhibition of autoimmune diabetes in NOD mice with serum from streptococcal preparation (OK‐432)‐injected mice | |
| PL195627B1 (pl) | Zastosowania kolostryniny, kompozycje farmaceutyczne do leczenia przewlekłych chorób ośrodkowego układu nerwowego lub immunostymulacji i zastosowanie nonapeptydu | |
| Belokrylov et al. | Immuno-, phagocytosis-modulating, and antitoxic properties of amino acids and peptide preparations | |
| WO2002013849A1 (en) | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines | |
| SUSZKO-PAWŁOWSKA et al. | Ovocystatin tetramer–effect on humoral immune response in SRBC-immunized mice and cytotoxic activity | |
| JP2001048804A (ja) | ＴＮＦ−α産生抑制剤 | |
| Eckert et al. | Splenopentin (DAc SP-5)—Accelerated Reconstitution of Antibody Formation after Syngeneic Bone Marrow Transplantation* |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |